UNC0646, 98%, a potent and selective G9a inhibitor with IC50 of 6 nM

Name: UNC0646, 98%, a potent and selective G9a inhibitor with IC50 of 6 nM | 1320288-17-2
Brand: J&K Chemical
SKU: JK1834957_10_MG
Price: 124.8 USD
Availability: OutOfStock

Cat. No JK1834957_10_MG

Vendor: J&K Chemical

Product Information

Product Name

UNC0646, 98%, a potent and selective G9a inhibitor with IC50 of 6 nM

Brand Name

J&K

Product Number

1834957

CAS

1320288-17-2

Molecular Formula

C36H59N7O2

Molecular Weight

621.90

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

53315882

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer’s Agent

Publication Name: ACS Medicinal Chemistry Letters

Publication Date: 2023-10-12

DOI: 10.1021/acsmedchemlett.3c00344

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Publication Name: Science Translational Medicine

Publication Date: 2023-06-21

DOI: 10.1126/scitranslmed.add7872

Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death

Publication Name: Toxicology in vitro : an international journal published in association with BIBRA

Publication Date: 2020-12

DOI: 10.1016/j.tiv.2020.104992

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle

Publication Name: ACS Chemical Biology

Publication Date: 2020-05-27

DOI: 10.1021/acschembio.0c00343

Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines

Publication Name: Journal of Medicinal Chemistry

Publication Date: 2011-08-05

DOI: 10.1021/jm200903z

UNC0646, 98%, a potent and selective G9a inhibitor with IC50 of 6 nM

Product Information

General Information

Safety Information

References Data Source From Pubchem

Repurposing of Raltitrexed as an Effective G9a/EHMT2 Inhibitor and Promising Anti-Alzheimer’s Agent

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death

High-Throughput Screening to Identify Inhibitors of the Type I Interferon–Major Histocompatibility Complex Class I Pathway in Skeletal Muscle

Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines